ReviewCancers2016
HPV Associated Head and Neck Cancer.
Review in Cancers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.
- A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The "ALARM" study.Cancer medicine · 2024Pooled it
- Trial
- Phytochemicals as Emerging Antiproliferative Agents in Head and Neck Cancer: Molecular Mechanisms and Therapeutic Strategies.Pharmacology · 2026Review
- A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).Frontiers in oncology · 2026Article
- The Clinicodemographic Features of Oral Squamous Cell Carcinoma: A Single-Centre Retrospective Study.International journal of dentistry · 2026Article
- Enhanced glycolysis and nicotinamide metabolism in HPV-positive head and neck cancer.Scientific reports · 2025Article
- Epidemiology of high-risk human papillomavirus among women of the north-central region of Ecuador: a retrospective study.Infectious agents and cancer · 2025Article
- Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.Oral oncology · 2025Article
- Prognostic and predictive roles of circulating microRNAs as biomarkers in head and neck cancer patients in the Northern Territory, Australia undergoing chemoradiotherapy-a pilot prospective cohort study.Translational cancer research · 2025Article
- Long non-coding RNAs as therapeutic targets in head and neck squamous cell carcinoma and clinical application.FEBS open bio · 2025Review
- Socio-demographic disparities in global trends of lip and oral cavity neoplasms from 1990 to 2021.Scientific reports · 2025Article
- Article
- Circulating M-MDSC Levels as an Assessment Marker for Post-Treatment Tumor Progression in Recurrent HNC Patients Following Radiation Therapy: A Case Series.Journal of clinical medicine · 2024Article
- Rare case of poorly differentiated squamous cell cancer of HPV etiology in a nasal polyp presenting as chronic sinusitis.Proceedings (Baylor University. Medical Center) · 2024Article
- Article
- Inequities in Screening and HPV Vaccination Programs and Their Impact on Cervical Cancer Statistics in Romania.Diagnostics (Basel, Switzerland) · 2023Article
- Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment.Vaccines · 2023Review
- Data mining on identifying diagnosis and prognosis biomarkers in head and neck squamous carcinoma.Scientific reports · 2023Article
- Human papillomavirus-associated head and neck squamous cell carcinoma cells rely on glycolysis and display reduced oxidative phosphorylation.Frontiers in oncology · 2023Article
- Human papillomavirus in oral squamous cell carcinoma using p16 and its co-relationship with cervical lymph node metastasis and clinicopathological parameters.Dental research journal · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck cancers (HNCs) are a highly heterogeneous group of tumours that are associated with diverse clinical outcomes. Recent evidence has demonstrated that human papillomavirus (HPV) is involved in up to 25% of HNCs; particularly in the oropharyngeal carcinoma (OPC) subtype where it can account for up to 60% of such cases. HPVs are double-stranded DNA viruses that infect epithelial cells; numerous HPV subtypes, including 16, 18, 31, 33, and 35, drive epithelial cell transformation and tumourigenesis. HPV positive (HPV+) HNC represents a distinct molecular and clinical entity from HPV negative (HPV-) disease; the biological basis for which remains to be fully elucidated. HPV positivity is strongly correlated with a significantly superior outcome; indicating that such tumours should have a distinct management approach. This review focuses on the recent scientific and clinical investigation of HPV+ HNC. In particular, we discuss the importance of molecular and clinical evidence for defining the role of HPV in HNC, and the clinical impact of HPV status as a biomarker for HNC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.